Sign in
4

Changes in Ownership

GeneDx Holdings Corp. Filed Acc 0001689575-26-000021

CHIEF EXECUTIVE OFFICER sold 46,933 shares at an average $63.17 ($2,964,841)

  • CHIEF EXECUTIVE OFFICER acquired 80,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Option exercise +80,000 138,447 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Sale −13,229 $61.29 $810,817 125,218 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Sale −5,117 $62.33 $318,952 120,101 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Sale −13,412 $63.28 $848,699 106,689 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Sale −5,292 $64.60 $341,859 101,397 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Sale −9,883 $65.21 $644,513 91,514 D
Derivatives
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-03-26 Option exercise · Restricted Stock Unit −80,000 160,000 D
Open-market sales · 46,933 sh · avg $63.17 · $2,964,841
Loading xslF345X06/form4-03302026_080325.xml…